Trends in prescribing as-needed inhaled corticosteroid (ICS)-Formoterol for patients with asthma - 07/02/23
Doi : 10.1016/j.rmed.2022.107096
Jiaying Li a, ⁎ 
, Katelyn R. Price b, Erin R. Weeda a, c, Sandra S. Garner a, c
, Katelyn R. Price b, Erin R. Weeda a, c, Sandra S. Garner a, c a Department of Pharmacy Services, Medical University of South Carolina, Charleston, SC, USA
b Medical University of South Carolina College of Pharmacy, Charleston, SC, USA
c Department of Clinical Pharmacy & Outcome Sciences, Medical University of South Carolina College of Pharmacy, Charleston, SC, USA
∗Corresponding author. Medical University of South Carolina Specialty Pharmacy, 230 Albemarle Road, Charleston, SC, 29407, USA.Medical University of South Carolina Specialty Pharmacy230 Albemarle RoadCharlestonSC29407USA
Highlights |
• | As-needed use of ICS-formoterol has not been well implemented in patients with asthma. |
• | Might be a lack of awareness of the updated recommendations from GINA report. |
• | Insurance coverage of as-needed ICS-formoterol may be limited by its off-label use. |
• | Areas for improvement available for pharmacist and other healthcare professionals to improve the implementation. |
Keywords : Inhaled corticosteroid, Formoterol, Asthma, GINA Report, As-needed
Plan
© 2022
Publié par Elsevier Masson SAS.
Vol 207
Article 107096- février 2023 Retour au numéro
Article précédent
- Does peak expiratory flow moderate trajectories of cognitive function among individuals with lung diseases? A longitudinal analysis of the National Health and Aging Trends Study
- Elise Wiley, Dina Brooks, Joy C. MacDermid, Brodie Sakakibara, Paul W. Stratford, Ada Tang
- How respiratory symptoms impact asthma-related quality of life in mild asthmatics
- Gilles Louis, Florence Schleich, Renaud Louis, Michèle Guillaume, Bernardo Sousa-Pinto, Jean Bousquet, Benoit Pétré
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?